IL42166A - Drug releasing preparation - Google Patents
Drug releasing preparationInfo
- Publication number
- IL42166A IL42166A IL42166A IL4216673A IL42166A IL 42166 A IL42166 A IL 42166A IL 42166 A IL42166 A IL 42166A IL 4216673 A IL4216673 A IL 4216673A IL 42166 A IL42166 A IL 42166A
- Authority
- IL
- Israel
- Prior art keywords
- plasticiser
- weight
- releasing preparation
- drug releasing
- solvent membrane
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 25
- 229940079593 drug Drugs 0.000 title claims 16
- 238000002360 preparation method Methods 0.000 title claims 16
- 239000004014 plasticizer Substances 0.000 claims abstract 20
- 239000012528 membrane Substances 0.000 claims abstract 18
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 claims abstract 5
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 claims abstract 3
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 3
- 229920001169 thermoplastic Polymers 0.000 claims abstract 3
- 239000002904 solvent Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 14
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- IRIAEXORFWYRCZ-UHFFFAOYSA-N Butylbenzyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IRIAEXORFWYRCZ-UHFFFAOYSA-N 0.000 claims 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 230000003014 reinforcing effect Effects 0.000 claims 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 4
- -1 diazepam Chemical class 0.000 claims 3
- ANPSOVQQJHCXHU-KVVVOXFISA-N 2,3-dihydroxypropyl (z)-octadec-9-enoate;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO ANPSOVQQJHCXHU-KVVVOXFISA-N 0.000 claims 2
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims 2
- GOJCZVPJCKEBQV-UHFFFAOYSA-N Butyl phthalyl butylglycolate Chemical group CCCCOC(=O)COC(=O)C1=CC=CC=C1C(=O)OCCCC GOJCZVPJCKEBQV-UHFFFAOYSA-N 0.000 claims 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 2
- 240000001879 Digitalis lutea Species 0.000 claims 2
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 claims 2
- CGSLYBDCEGBZCG-UHFFFAOYSA-N Octicizer Chemical compound C=1C=CC=CC=1OP(=O)(OCC(CC)CCCC)OC1=CC=CC=C1 CGSLYBDCEGBZCG-UHFFFAOYSA-N 0.000 claims 2
- YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 claims 2
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical group OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 2
- 229960000836 amitriptyline Drugs 0.000 claims 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229940125715 antihistaminic agent Drugs 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims 2
- 229960002028 atropine sulfate Drugs 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 150000001557 benzodiazepines Chemical class 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- XXLZPUYGHQWHRN-RPBOFIJWSA-N dehydroemetine Chemical compound COC1=C(OC)C=C2[C@@H]3CC(C[C@@H]4C5=CC(OC)=C(OC)C=C5CCN4)=C(CC)CN3CCC2=C1 XXLZPUYGHQWHRN-RPBOFIJWSA-N 0.000 claims 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 2
- 229960003529 diazepam Drugs 0.000 claims 2
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 claims 2
- 229960001912 dicoumarol Drugs 0.000 claims 2
- HIZKPJUTKKJDGA-UHFFFAOYSA-N dicumarol Natural products O=C1OC2=CC=CC=C2C(=O)C1CC1C(=O)C2=CC=CC=C2OC1=O HIZKPJUTKKJDGA-UHFFFAOYSA-N 0.000 claims 2
- 229960003061 dihydroemetine Drugs 0.000 claims 2
- MIMDHDXOBDPUQW-UHFFFAOYSA-N dioctyl decanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCC MIMDHDXOBDPUQW-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- YAFOVCNAQTZDQB-UHFFFAOYSA-N octyl diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(OCCCCCCCC)OC1=CC=CC=C1 YAFOVCNAQTZDQB-UHFFFAOYSA-N 0.000 claims 2
- 229960005222 phenazone Drugs 0.000 claims 2
- 235000021317 phosphate Nutrition 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 125000005498 phthalate group Chemical class 0.000 claims 2
- 239000004800 polyvinyl chloride Substances 0.000 claims 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims 2
- 235000012424 soybean oil Nutrition 0.000 claims 2
- 239000003549 soybean oil Substances 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- 229960000278 theophylline Drugs 0.000 claims 2
- 239000003204 tranquilizing agent Substances 0.000 claims 2
- 230000002936 tranquilizing effect Effects 0.000 claims 2
- HVDSDWIAUZSOKB-UHFFFAOYSA-N tris(3-ethyloctan-3-yl) phosphate Chemical compound CCCCCC(CC)(CC)OP(=O)(OC(CC)(CC)CCCCC)OC(CC)(CC)CCCCC HVDSDWIAUZSOKB-UHFFFAOYSA-N 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 230000002763 arrhythmic effect Effects 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 229940075065 polyvinyl acetate Drugs 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 claims 1
- 229960000244 procainamide Drugs 0.000 claims 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 abstract 1
- 229940116351 sebacate Drugs 0.000 abstract 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The solubility membrane is a plasticiser contg. a thermoplastic polymer esp. PVC or PVA contg. >=40% and pref. 80% plasticiser esp. an adipate, sebacate, phosphate or phthalate digitables is compressed into a tablet with lactose which is then dipped into a soln. of cyclohexanone contg. 8% dioctyl phthalate and 2% PVC and dried.
[FR2227875A1]
Claims (26)
1. Process for the manufacture of a drug releasin preparation, comprising encapsulating or coating a therapeutic agent in or with a solvent membrane, as hereinbefore defined.
2. Process according to claim 1, wherein there is used a solvent membrane comprising at least one plasticiser and at least one polymer reinforcing said plasticiser.
3. 5. Process according to claim 1 or 2, wherein there is used a solvent membrane comprising a plasticiser and a thermoplastic polymer reinforcing said plasticiser.
4. Process according to claim 1, 2 or 3, wherein there is used a solvent membrane wherein the polymer is poly-vinylchloride or pol vinylace ate.
5. Process according to any one of claims 1 to 4, wherein there is used a solvent membrane wherein the plasticiser is selected from the group consisting of adipates, eebacates, phosphates and phthalates.
6. Process according to any one of claims 1 to 5, wherein there is used a solvent membrane wherein the plasticiser is selected from the group consisting of butyl-phthalyl-butyl-glycolate, epoxidised soy bean oil, tri-tolyl- phosphate, dibutyl sebacate, dioctyl sebacate, tri-(diethyl-hexyl)-phosphate , 2-ethyl-hexyl-diphenyl phosphate, di-iso-butyl adipate fmethyl stearate, glycerol glyceryl monooleate, butylbenzyl phthalate, dioctyl phthalate, diphenyl-octyl phosphate, diethyl phthalate, di-(2-ethyl-hexyl)-phthalate and TBP.
7. Process according to any one of claims 1 to 6, wherein the plasticiser is used in an amount of at least 40$ by weight of the weight of the solvent membrane.
8. Process according to any one of claims 1 to 7, wherein the plasticiser is used in an amount of at least about 60$ by weight of the weight of the solvent membrane.
9. · Process according to any one of claims 1 to 8, wherein the plasticiser is used in an amount of a least about 80$ by weight of the weight of the solvent membrane.
10. Process accordin to any one of claims 1 to 9, wherein the therapeutic agent is selected from the group consisting of steroids, vitamins, antihistamines, stimulants, tranquilizers, antibiotics and arrhythmic agents.
11. Process according to any one of claims 1 to 10, wherein the therapeutic agent is selected from the group consisting of digitalis, antipyrine, procainamide hydrochlorid atropine sulfate, theophylline and dicumarol.
12. Process according to any one of claims 1 to 10, wherein the therapeutic agent is selected from the group consisting of benzodiazepines e.g. diazepam, triptylines e.g. amitriptyline , and dehydroemetine.
13. Process for the manufacture of a drug releasing preparation as hereinbefore particularly described, especially with reference to the foregoing examples.
14. A drug release preparation comprising a therapeutic agent encapsulated in or coated with a solvent membrane, whenever prepared by the process as claimed in any one of claims 1 to 13» or by an obvious equivalent thereof.
15. A drug releasing preparation which comprises a therapeutic agent being encapsulated in or coated by a solvent membranef as hereinbefore defined.
16. A drug releasing preparation according to claim 15, wherein the solvent membrane comprises at least one plasticiser and at least a polymer reinforcing said plasticiser.
17. A drug releasing preparation according to claim 15 or 16, wherein the solvent membrane comprises a plasticiser and a thermoplastic polymer reinforcing said plasticiser.
18. A drug releasing preparation according to claim 15, 16 or 17» wherein the polymer is polyvinylchloride or poly-vinylacetate.
19. A drug releasing preparation according to any one of claims 15 to 18, wherein the solvent membrane comprises a plasticiser selected from the group consisting of adipates, sebacates, phosphates and phthalates.
20. A drug releasing preparation according to any one of claims 15 to 19, wherein the solvent membrane comprises a plasticiser selected from the group consisting of butyl-phthalyl-butyl-glycolate, epoxidised soy bean oil, tri-tolyl-phosphate, dibutyl sebacate, dioctyl sebacate, tri-(diethyl-hexyl)-phosphate, 2-ethyl-hexyl-diphenyl phosphate, di-iso-butyl adipate,methyl stearate, glycerol glyceryl monooleate, butyl-benzyl phthalate , dioctyl phthalate, diphenyl-octyl phosphate, diethyl phthalate, di~(2-ethyl-hexyl)-phthalate and TBP.
21. A drug releasing preparation according to any one of claims 15 to 20, wherein the plasticiser is present in an amount of at least 40 by weight of the weight of the solvent membrane .
22. A drug releasing preparation according to an one of claims 15 to 21, wherein the plasticiser is present in an amount of at least about 60$ by weight of the weight of the solvent membrane.
23. A drug releasing preparation according to any one of claims 15 to 22, wherein the plasticiser is present in an amount of at least about 80$ by weight of the weight of the solvent membrane.
24. A drug releasing preparation according to any one of claims 15 to 23, wherein the therapeutic agent is selected from the group consisting of steroids, vitamins, antihistamines, stimulants, tranquilizers, antibiotics and arrjiytraic . agents. ■ ' '
25. A drug releasing preparation according to any one of claims 15 to 24, wherein the therapeutic agent is selected from the group consisting of digitalis, antipyrine, procainamid hydrochloride, atropine sulfate, theophylline and dicumarol.
26. A drug releasing preparation according to an one of claims 15 to 24, wherein the therapeutic agent is selected from the group consisting of benzodiazepines e.g. diazepam, triptylines e.g. amitriptyline , and dehydroemetine. For the Applicants Dr.Yitzhak Hess
0. ,\ m
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL42166A IL42166A (en) | 1973-05-02 | 1973-05-02 | Drug releasing preparation |
| ZA00742682A ZA742682B (en) | 1973-05-02 | 1974-04-29 | Drug delivery preparation with controlled release time and rate |
| AU68402/74A AU6840274A (en) | 1973-05-02 | 1974-04-30 | Composition |
| FR7415014A FR2227875A1 (en) | 1973-05-02 | 1974-04-30 | Slow release agents for drugs - comprising drugs enrobed or encapsulated with a solubility |
| DE2421016A DE2421016A1 (en) | 1973-05-02 | 1974-04-30 | PREPARATION |
| JP49048382A JPS5029731A (en) | 1973-05-02 | 1974-05-01 | |
| BE143873A BE814491A (en) | 1973-05-02 | 1974-05-02 | PHARMACEUTICAL COMPOSITION RELEASING THE ACTIVE SUBSTANCE AT A PRE-DETERMINED RATE. |
| NL7405903A NL7405903A (en) | 1973-05-02 | 1974-05-02 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL42166A IL42166A (en) | 1973-05-02 | 1973-05-02 | Drug releasing preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL42166A0 IL42166A0 (en) | 1973-07-30 |
| IL42166A true IL42166A (en) | 1976-01-30 |
Family
ID=11047093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL42166A IL42166A (en) | 1973-05-02 | 1973-05-02 | Drug releasing preparation |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS5029731A (en) |
| AU (1) | AU6840274A (en) |
| BE (1) | BE814491A (en) |
| DE (1) | DE2421016A1 (en) |
| FR (1) | FR2227875A1 (en) |
| IL (1) | IL42166A (en) |
| NL (1) | NL7405903A (en) |
| ZA (1) | ZA742682B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE426548B (en) * | 1978-12-05 | 1983-01-31 | Haessle Ab | SOLID PHARMACEUTICAL PREPARATION INCLUDING A THERAPEUTICALLY EFFECTIVE HEART GYCLOSIDE AND POLYMER |
| SE7813246L (en) * | 1978-12-22 | 1980-06-23 | Haessle Ab | FIXED PHARMACEUTICAL PREPARATION INCLUDING BODIES WITH MULTIPLE LAYERS |
-
1973
- 1973-05-02 IL IL42166A patent/IL42166A/en unknown
-
1974
- 1974-04-29 ZA ZA00742682A patent/ZA742682B/en unknown
- 1974-04-30 DE DE2421016A patent/DE2421016A1/en active Pending
- 1974-04-30 AU AU68402/74A patent/AU6840274A/en not_active Expired
- 1974-04-30 FR FR7415014A patent/FR2227875A1/en active Granted
- 1974-05-01 JP JP49048382A patent/JPS5029731A/ja active Pending
- 1974-05-02 BE BE143873A patent/BE814491A/en unknown
- 1974-05-02 NL NL7405903A patent/NL7405903A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5029731A (en) | 1975-03-25 |
| DE2421016A1 (en) | 1974-11-21 |
| NL7405903A (en) | 1974-11-05 |
| ZA742682B (en) | 1975-08-27 |
| BE814491A (en) | 1974-09-02 |
| IL42166A0 (en) | 1973-07-30 |
| AU6840274A (en) | 1975-10-30 |
| FR2227875A1 (en) | 1974-11-29 |
| FR2227875B1 (en) | 1977-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3965255A (en) | Controlled drug releasing preparations | |
| CA1289075C (en) | Pharmaceutical preparation | |
| CA2074309C (en) | Stabilized controlled release formulations having acrylic polymer coating | |
| US4557925A (en) | Membrane-coated sustained-release tablets and method | |
| US4629620A (en) | Membrane-coated sustained-release tablets and method | |
| US4891230A (en) | Diltiazem formulation | |
| US4917899A (en) | Controlled absorption diltiazem formulation | |
| EP0587220B1 (en) | Enteric coated soft capsules and method of preparation thereof | |
| EP0250267B1 (en) | Controlled absorption pharmaceutical composition | |
| EP0583244B1 (en) | Method of producing zero-order controlled-release devices | |
| US5976571A (en) | Method for making a multi-stage drug delivery system | |
| US5219621A (en) | Methods of treatment with diltiazem formulations | |
| IE58263B1 (en) | Controller-release medical preparations | |
| GB908016A (en) | Prolonged release medicament and a method of producing the same | |
| EP0340305B1 (en) | Hemolysis inhibitor and plasticizer | |
| AU8025987A (en) | Coating membrane and compositions prepared therefrom | |
| DE3373781D1 (en) | Process for preparing a pharmaceutical formulation in the form of a polyacrylate film | |
| GB1072055A (en) | Plasticized ethylene copolymers | |
| US3520970A (en) | Solid oral drug medicament coated for rapid or gradual release with copolymers of polymerizable quaternary ammonium monomers and water-insoluble homopolymer-forming monomers | |
| KR970001656B1 (en) | Controlled Absorption Diltiazem Formulation | |
| IL42166A (en) | Drug releasing preparation | |
| GB1593062A (en) | Coatings | |
| GB2165517A (en) | Micro-encapsulation of medicaments | |
| US4629619A (en) | Membrane-coated sustained-release tablets and method | |
| US2830010A (en) | Powder-filled hexylresorcinol capsules |